McClellan WM - Search Results

1

The epidemic of renal disease--what drives it and what can be done?

McClellan WM. McClellan WM. Nephrol Dial Transplant. 2006 Jun;21(6):1461-4. doi: 10.1093/ndt/gfi317. Nephrol Dial Transplant. 2006. PMID: 16714335 No abstract available.

2

Contribution of anaemia to progression of renal disease: a debate.

Rossert JA, McClellan WM, Roger SD, Verbeelen DL, Hörl WH. Rossert JA, et al. Among authors: mcclellan wm. Nephrol Dial Transplant. 2002;17 Suppl 1:60-6. doi: 10.1093/ndt/17.suppl_1.60. Nephrol Dial Transplant. 2002. PMID: 11812915 Review.

3

Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney disease.

Rizk DV, Gutierrez O, Levitan EB, McClellan WM, Safford M, Soliman EZ, Warnock DG, Muntner P. Rizk DV, et al. Among authors: mcclellan wm. Nephrol Dial Transplant. 2012 Sep;27(9):3482-8. doi: 10.1093/ndt/gfr684. Epub 2011 Dec 13. Nephrol Dial Transplant. 2012. PMID: 22167594 Free PMC article.

4

Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009.

Regidor D, McClellan WM, Kewalramani R, Sharma A, Bradbury BD. Regidor D, et al. Among authors: mcclellan wm. Nephrol Dial Transplant. 2011 May;26(5):1583-91. doi: 10.1093/ndt/gfq573. Epub 2010 Sep 22. Nephrol Dial Transplant. 2011. PMID: 20861195 Clinical Trial.

5

Exploration of anaemia as a progression factor in African Americans with cardiovascular disease.

Newsome BB, Onufrak SJ, Warnock DG, McClellan WM. Newsome BB, et al. Among authors: mcclellan wm. Nephrol Dial Transplant. 2009 Nov;24(11):3404-11. doi: 10.1093/ndt/gfp304. Epub 2009 Aug 23. Nephrol Dial Transplant. 2009. PMID: 19703835

6

Progression of renal disease--can we forget about inhibition of the renin-angiotensin system?

Mann JF, McClellan WM, Kunz R, Ritz E. Mann JF, et al. Among authors: mcclellan wm. Nephrol Dial Transplant. 2006 Sep;21(9):2348-51; discussion 2352-3. doi: 10.1093/ndt/gfl315. Epub 2006 Jul 5. Nephrol Dial Transplant. 2006. PMID: 16822789 Review. No abstract available.

7

Epoetin treatment: what are the arguments to expect a beneficial effect on renal disease progression?

Rossert J, McClellan WM, Roger SD, Verbeelen DL. Rossert J, et al. Among authors: mcclellan wm. Nephrol Dial Transplant. 2002 Mar;17(3):359-62. doi: 10.1093/ndt/17.3.359. Nephrol Dial Transplant. 2002. PMID: 11865076 Review. No abstract available.

8

Effect of community characteristics on familial clustering of end-stage renal disease.

Song EY, McClellan WM, McClellan A, Gadi R, Hadley AC, Krisher J, Clay M, Freedman BI. Song EY, et al. Among authors: mcclellan wm, mcclellan a. Am J Nephrol. 2009;30(6):499-504. doi: 10.1159/000243716. Epub 2009 Sep 30. Am J Nephrol. 2009. PMID: 19797894 Free PMC article.

9

Population-based screening for family history of end-stage renal disease among incident dialysis patients.

Freedman BI, Volkova NV, Satko SG, Krisher J, Jurkovitz C, Soucie JM, McClellan WM. Freedman BI, et al. Among authors: mcclellan wm. Am J Nephrol. 2005 Nov-Dec;25(6):529-35. doi: 10.1159/000088491. Epub 2005 Sep 21. Am J Nephrol. 2005. PMID: 16179780

10

Chronic kidney disease is often unrecognized among patients with coronary heart disease: The REGARDS Cohort Study.

McClellan WM, Newsome BB, McClure LA, Cushman M, Howard G, Audhya P, Abramson JL, Warnock DG. McClellan WM, et al. Am J Nephrol. 2009;29(1):10-7. doi: 10.1159/000148645. Epub 2008 Jul 26. Am J Nephrol. 2009. PMID: 18663284 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results